Baxter International (BAX) EBITDA (2009 - 2026)

Baxter International (BAX) has 18 years of EBITDA data on file, last reported at $66.0 million in Q1 2026.

• EBITDA for Q1 2026 came in at $66.0 million, down 65.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $514.0 million (down 51.23% YoY), and the FY2025 annual result was -$308.0 million, down 2300.0% from the prior year.
• EBITDA improved to $66.0 million in Q1 2026 per BAX's latest filing, from -$33.0 million in the prior quarter.
• Over five years, EBITDA peaked at $2.6 billion in Q3 2023 and troughed at -$2.9 billion in Q3 2022.
• A 5-year average of $102.9 million and a median of $146.0 million in 2022 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2023: EBITDA sank 1456.52% in 2022, then soared 307.05% in 2023.
• A 5-year view of EBITDA shows it stood at -$312.0 million in 2022, then soared by 307.05% to $646.0 million in 2023, then surged by 48.45% to $959.0 million in 2024, then plunged by 103.44% to -$33.0 million in 2025, then soared by 300.0% to $66.0 million in 2026.
• Business Quant data shows BAX's EBITDA at $66.0 million in Q1 2026, -$33.0 million in Q3 2025, and $287.0 million in Q2 2025.